Nika Pharmaceuticals Reports Increased Net Loss and No Revenue in Q1 2026

Nika Pharmaceuticals, Inc. reported a net loss of $13,359 for the first quarter of 2026, a slight increase from the net loss of $12,945 recorded in the same period of 2025. The company did not generate any revenue during this quarter, maintaining a consistent trend from previous periods. Operating expenses rose to $13,359, up from $12,945 in the prior year, primarily driven by increased general and administrative costs, which amounted to $2,639 compared to $1,800 in the previous year. Professional fees decreased slightly to $10,720 from $11,145, reflecting ongoing legal and accounting expenses.

As of March 31, 2026, Nika Pharmaceuticals reported total assets of $20,637,000, a decrease from $20,996,000 at the end of 2025. Current liabilities increased to $331,624 from $318,624, primarily due to amounts owed to related parties. The company’s stockholders' deficit widened to $310,987 from $297,628, attributed to the accumulated deficit of $9,017,368. The company continues to rely on loans from related parties to fund its operations, raising concerns about its ability to continue as a going concern.

Strategically, Nika Pharmaceuticals has been active in expanding its business operations. The company completed a merger with Nika BioTechnology, Inc. in February 2024, which increased its ownership stake in Nika Europe, Ltd. to 80%. This merger is expected to enhance Nika's market presence in Europe, Asia, and Africa, as the company prepares to construct a pharmaceutical factory for drug production. Additionally, Nika has entered into several exclusive rights agreements for the production and distribution of various pharmaceutical products and dietary supplements, which are anticipated to bolster its product offerings.

Operationally, Nika Pharmaceuticals has not reported significant changes in customer counts or user statistics, as it has yet to generate revenue. The company’s employee headcount remains stable, with no new hires or layoffs reported in the latest filing. The company’s focus on geographic expansion and product adoption is evident in its strategic agreements, which aim to establish a foothold in multiple international markets.

Looking ahead, Nika Pharmaceuticals acknowledges the challenges it faces, particularly regarding its financial sustainability and the need for additional capital. The company is exploring options to raise funds through equity or debt offerings. Management remains optimistic about the potential of its strategic initiatives, including the construction of the new pharmaceutical factory and the expansion of its product lines, which they believe could lead to future revenue generation. However, the lack of current income and reliance on related party loans raises substantial doubt about the company's ability to continue operations without significant changes in its financial structure.